Previous Article | Next Article ![]()
Journal of Clinical Microbiology, November 2004, p. 5298-5301, Vol. 42, No. 11
0095-1137/04/$08.00+0 DOI: 10.1128/JCM.42.11.5298-5301.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Infectious Diseases Section,1 Research Service, Veterans Affairs Medical Center West Los Angeles,4 Department of Medicine,2 Department of Microbiology, Immunology and Molecular Genetics, University of California at Los Angeles School of Medicine, Los Angeles, California,3 Department of Medical Microbiology, Turku University, Turku,6 Department of Bacteriology Anaerobe Reference Laboratory, National Public Health Institute (KTL), Helsinki, Finland5
Received 24 December 2003/ Returned for modification 12 March 2004/ Accepted 15 July 2004
|
|
|---|
-fucosidase and glyoxylic acid positivity. The novel species is difficult to differentiate from P. endodontalis phenotypically and was designated a P. endodontalis-like organism for some time. However, P. endodontalis is recovered almost exclusively from oral sources and also grows poorly on Biolog Universal Agar, both characteristics that are in contrast to those of the other two organisms. Furthermore, P. uenonis is glycerol positive in the Biolog AN Microplate system. Both P. asaccharolytica and P. uenonis are positive by 13 other tests in the Biolog system, whereas P. endodontalis is negative by all of these tests. P. asaccharolytica grew well in both solid and liquid media without supplementation with 5% horse serum, whereas the other two species grew poorly without supplementation. Sequencing of 16S rRNA revealed about 10% divergence between the novel species and P. endodontalis but less than 2% sequence difference between the novel species and P. asaccharolytica. Subsequent DNA-DNA hybridization studies documented that the novel organism was indeed distinct from P. asaccharolytica. We propose the name Porphyromonas uenonis for the novel species. We have recovered P. uenonis from four clinical infections in adults, all likely of intestinal origin, and from the feces of six children. |
|
|---|
|
|
|---|
The fecal strains were isolated during a microbiological study of antimicrobial agent-associated flora changes. The fecal samples were inoculated on various selective and nonselective media by quantitative culture techniques (6). For the isolation of the novel organism, brucella blood agar and kanamycin-vancomycin laked blood agar (KVLB) and phenylethyl alcohol blood agar (PEA) plates were incubated anaerobically for up to 10 days and were then examined; all but one strain grew within 7 days. The clinical WAL strains were characterized as part of a comprehensive reevaluation of pigmented gram-negative rods; they generally grew within 3 days.
Identification by conventional methods. The strains were characterized by routine biochemical tests (5, 6) by using prereduced anaerobically sterilized biochemicals, gas-liquid chromatography for metabolic end products (6), API ZYM panels (BioMerieux, Marcy l'Etoile, France), the RapID ANA II system (Remel, Lenexa, Kans.), the AN Microplate system (Biolog, Hayward, Calif.), and Rosco (Taastrup, Denmark) diagnostic tablets. The production of ß-lactamase was detected by the nitrocefin disk test (Biodisk). Antimicrobial susceptibility studies were done with three strains and various antimicrobial agents by the NCCLS-approved Wadsworth agar dilution method (8).
Cellular fatty acid analysis. Cellular fatty acids were detected with a Hewlett-Packard 5890 series II gas chromatograph and Microbial Identification System software (MIDI, Newark, N.J.). The isolates were grown on supplemented brain heart infusion agar with blood, and the bacterial mass was harvested directly from the plates because of poor growth in liquid medium. The corresponding library (ANAEROBE, version Moore 5.0) was used in successive analyses.
Genotypic characterization. The mole percent G+C contents of the organism DNAs were determined by high-pressure liquid chromatography (7). The 16S rRNA genes were amplified by PCR, and the products were sequenced directly with a Biotech Diagnostic (Laguna Niguel, Calif.) Big Dye sequencing kit on an ABI 377 sequencer (Applied Biosystems, Foster City, Calif.). The sequences obtained were compared with the sequences in the GenBank database by using BLAST software (1), and the percent similarity to other sequences was determined. Closely related sequences were retrieved from GenBank and were aligned with the newly determined sequences by using the program DNA Tools (10). The resulting multiple-sequence alignment (with approximately 100 bases at the 5' end of the molecule omitted from further analysis because of alignment uncertainties due to highly variable region V1) was analyzed with the program GeneDoc (9). DNA-DNA reassociation experiments were done by the spectrophotometric method of De Ley et al. (2) with a Gilford system model 2600 spectrophotometer equipped with a Gilford model 2527-R thermal programmer.
Nucleotide sequence accession number. The GenBank accession number for P. uenonis is AY570514.
|
|
|---|
The novel species was detected in fecal specimens of 6 of 30 children. It was isolated only from the area of heavy growth on brucella blood agar, KVLB, or PEA plates and not as single colonies. In the initial cultures, an incubation time of at least 7 days was required before the pigmentation of the novel species, which assisted in its recognition, was detected. On subculture, growth and colony pigmentation occurred in 3 days on laked rabbit blood agar. The counts of the novel species in the fecal samples were low (<103 CFU/g).
All isolates of the novel species were sensitive to the vancomycin special-potency disk, and all except one isolate were resistant to the kanamycin and colistin special-potency disks; the one isolate that was the exception was sensitive to colistin. Colonies produced a black pigment (Fig. 1) after 3 days of incubation on laked rabbit blood agar and exhibited red fluorescence under UV light (366 nm) earlier than that. There was weak beta-hemolysis on blood agar plates. Both the novel species and P. asaccharolytica grew better on Biolog Universal Agar (BUA) than on brucella blood agar; P. endodontalis grew poorly on BUA. P. uenonis strains were indole positive; were lipase, catalase, and nitrate negative; were inhibited by bile; were asaccharolytic; and produced acetic, propionic, isobutyric, butyric, isovaleric, and succinic acids as metabolic end products. The API ZYM kit gave positive reactions for alkaline phosphatase, esterase, esterase lipase, acid phosphatase, and naphthol-AS-BI phosphohydrolase and variable reactions for leucine arylamidase. The organism was negative for
-fucosidase, the enzyme that distinguishes P. asaccharolytica from P. endodontalis, both by the API ZYM test and with Rosco diagnostic tablets. None of the tests applied by the RapID ANA II system except for the aforementioned
-fucosidase test reliably distinguished between the three species under consideration. The codes generated by the RapID ANA II system differed only by the
-fucosidase test. The Biolog AN Microplate 95 test card, which was used to test four wild strains of P. uenonis and the type strains of all three species, also consistently showed a positive
-fucosidase test result only for P. asaccharolytica; but, in addition, it showed that P. asaccharolytica was the only one of the three species positive for glyoxylic acid, and among the three species, only P. uenonis was positive for glycerol. Both P. asaccharolytica and P. uenonis tested positive and P. endodontalis tested negative by a number of other tests: D-cellobiose, dextrin, D-galacturonic acid, gentibiose,
-D-glucose, glucose-6-phosphate, maltose, D-mannose, 3-methyl-D-glucose, ß-methyl-D-glucose, D-trehalose, turanose, and
-ketobutyric acid (despite the designation "asaccharolytica" for P. asaccharolytica). Antimicrobial susceptibility tests, usually one strain per drug, revealed that the novel species was highly susceptible (MIC, <1 µg/ml) to amoxicillin-clavulanate, piperacillin-tazobactam, ticarcillin-clavulanate, imipenem, meropenem, ceftizoxime, clindamycin, trovafloxacin, gemifloxacin, and metronidazole. Two isolates produced ß-lactamases, and their susceptibilities to penicillin G and ampicillin were variable. The ciprofloxacin MIC for one strain was 2 µg/ml. One strain was highly resistant to trimethoprim-sulfamethoxazole. Testing with prereduced anaerobically sterilized biochemicals was not helpful in distinguishing the three species.
![]() View larger version (45K): [in a new window] |
FIG. 1. Colonial appearance on blood agar plates after 7 days of incubation. P. endodontalis grew poorly on BUA. Note the differences in the degrees of pigmentation.
|
|
View this table: [in a new window] |
TABLE 1. Differential characteristics of selected Porphyromonas speciesa
|
![]() View larger version (47K): [in a new window] |
FIG. 2. Unrooted tree showing the phylogenetic position of P. uenonis sp. nov. within the Bacteroides subgroup of the cytophaga-flavobacter-bacteroides phylum. The tree was constructed by the maximum-parsimony method and is based on a comparison of approximately 1,400 nucleotides. Bootstrap values, expressed as a percentage of 1,000 replications, are given at the branching points. The scale bar indicates 1% sequence divergence. Superscript letters: a, "Porphyromonas canis" is not a valid species; Superscript letters: b, Porphyromonas salivosa is a junior synonym of Porphyromonas macacae (6a). Although P. crevioricanis and P. gingicanis are valid species (4), their 16S rRNA gene sequences are not available in public databases; therefore, they are not included in the phylogenetic tree.
|
|
|
|---|
-fucosidase positive (3) and glyoxylic acid positive. Sequencing of 16S rRNA readily distinguishes between P. endodontalis and P. uenonis, but DNA-DNA reassociation studies are required to distinguish genetically between P. asaccharolytica and P. uenonis. The novel species described here, P. uenonis, appears to be of relatively low virulence since it was always found in mixed culture and was not recovered in blood cultures or from patients with serious infections. It is also quite susceptible to most antimicrobial agents, although ß-lactamase production was noted in some strains. More data on the range and types of infections that this organism causes and its antimicrobial susceptibility are needed.
Description of P. uenonis sp. nov.
Porphyromonas uenonis (uenonis, to honor the Japanese microbiologist Kazue Ueno, who has contributed so much to our knowledge of gram-negative anaerobic rods and anaerobic bacteriology in general) cells are gram-negative rods. The organism is obligately anaerobic. Growth is stimulated by 5% horse serum and similar additives. Black pigment occurs in colonies on blood-containing agar media after 7 or more days of incubation for primary isolation and after 3 days on laked rabbit blood agar for subsequent subculture. Weak beta-hemolysis is noted on brucella blood agar. Colonies exhibit red fluorescence under long-wave UV light, especially before pigment has developed. The organism is asaccharolytic except in the Biolog AN Microplate system; the metabolic end products found by gas-liquid chromatography are acetic, propionic, isobutyric, butyric, isovaleric, and succinic acids. The organism is indole positive; is lipase, catalase, and nitrate negative; and is inhibited by bile. Positive reactions for alkaline phosphatase, esterase, esterase lipase, acid phosphatase, and naphthol-AS-BI phosphohydrolase are detected; and variable reactions for leucine arylamidase are detected. The organism is negative for
-fucosidase. The principal cellular fatty acid is iso-C15:0. Some strains produce ß-lactamase. The organism is susceptible to most antimicrobial agents. It is found as part of a mixed flora in various infections, which apparently have their origin in the intestinal tract. The organism's habitat is probably the human gut. The type strains are WAL 9902, ATCC BAA-906, and CCUG 48615. The G+C content of the type strain is 52.5 mol%.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»